Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06688461

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

A recognized driver for cardiovascular complications of type 2 diabetes mellitus (T2DM) is impaired plasma glucose homeostasis as consequence of skeletal muscle insulin resistance. Insulin-mediated plasma glucose disposal in skeletal muscle comprises oxidative glucose disposal (cellular glucose uptake for oxidation) and non-oxidative glucose disposal (NOGD; cellular glucose uptake for storage as glycogen), both processes being impaired in T2DM patients. Excessive intrahepatic fat accumulation (particularly monounsaturated (MUFA) and saturated (SFA)) is commonly observed in T2DM patients and tightly associates with plasma glucose dysregulation. It has been hypothesized that skeletal muscle insulin resistance redistributes circulating glucose away from muscle which together with hyperinsulinemia promotes intrahepatic lipid accretion via de novo lipogenesis (DNL). As saturated lipids is the final product of DNL, improving skeletal muscle insulin sensitivity, next to enhance plasma glucose homeostasis, might lower intrahepatic lipid content particularly intrahepatic saturated lipids.

Regular exercise is a cornerstone in the treatment of T2DM and to improve skeletal muscle insulin sensitivity. Interestingly, a conventional exercise program (aerobic-type combined with strength-type exercise) restores insulin-stimulated oxidative glucose disposal in T2DM patients to levels observed in age-matched normoglycemic subjects. Non-oxidative glucose disposal (NOGD), however, does not improve upon such conventional exercise programs. In this regard, for full restoration of compromised glucose disposal, it is pivotal to come up with effective training methods to target NOGD. High intensity interval training (HIIT) has the potential to expands the glycogen synthesis capacity in athletes by repetitive cycles of glycogen depletion/repletion, hence holds promise to improve NOGD in T2DM patients. Of note, HIIT also lowers the intrahepatic fat content in pre-diabetes individuals. Nevertheless, whether HIIT reduces the intrahepatic fat content and modifies its composition in T2DM patients is unknown. In this regard, it is hypothesized that HIIT expands the NOGD capacity in skeletal muscle of overweight/obese type 2 diabetes patients. By doing so, it is postulated that HIIT improves skeletal muscle insulin sensitivity and therefore benefits the 24 hours glycaemic profile in T2DM patients. In line, it is hypothesized that the HIIT-mediated improvements on NOGD and skeletal muscle insulin sensitivity coexist with the reduction of intrahepatic lipid content -particularly reduced saturated lipids- via lowering DNL.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Finis Terrae University

Santiago, Chile

Location status: Recruiting

Location contact

Rodrigo Mancilla, PhD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants are able to provide signed and dated written informed consent prior to any study specific procedures
  • Aged ≥ 45 and ≤ 75 years
  • BMI: 25-35 kg/m2
  • Diagnosed as T2DM patients for at least 1 year and not longer than 5 years
  • HbA1c ≥ 6.5% and ≤ 8.5%
  • Fasting blood glucose <130 mg/dL
  • Women are post-menopausal (>1 year cessation of menses),
  • Being stable on medication use of metformin and/or sulfonylurea derivatives for the previous 3 months or more and other medication naïve.

Exclusion criteria

  • Type 1 diabetes
  • Patients with congestive heart failure and and/or severe renal and or liver insufficiency
  • Contraindications for MRI/MRS examination
  • Active diabetic foot
  • Polyneuropathy or retinopathy
  • Signs of active liver or kidney dysfunction
  • BMI >35 kg/m2
  • Exogeneous insulin therapy
  • Use of antidiabetic medication other than metformin or sulfonylurea derivatives treatment within 3 months before screening
  • Use of SGLT2 inhibitors
  • Unstable body weight (variations >5kg in the last 3 months)
  • Ongoing weight loss diet or use of weight loss agents
  • Uncontrolled hypertension
  • Engagement in regular exercise program or any other medical condition that will impede the safe performance of the experiments

Treatment and study plan

Experimental group: Exercise training

Other

HIIT program, 3 times per week for 12 weeks

Primary outcomes

  1. Insulin-stimulated non-oxidative plasma glucose disposal (NOGD)

    Time frame: 12 weeks

    Insulin-stimulated NOGD will be measured upon hyperinsulinemic-euglycemic clamp test

Secondary outcomes

  1. Skeletal muscle insulin sensitivity

    Time frame: 12 weeks

    Skeletal muscle insulin sensitivity will be measured as the rate of insulin-stimulated plasma glucose disposal (Rd) measured upon hyperinsulinemic-euglycemic clamp test

Other outcomes

  1. Insulin-stimulated glucose oxidation

    Time frame: 12 weeks

    Insulin-stimulated glucose oxidation will be measured via indirect calorimetry during clamp test

  2. Metabolic flexibility

    Time frame: 12 weeks

    Metabolic flexibility will be measured via indirect calorimetry during the clamp test

  3. Liver insulin sensitivity

    Time frame: 12 weeks

    Liver insulin sensitivity will be measured as the rate of insulin-mediated suppression of endogenous glucose production (EGP) upon hyperinsulinemic-euglycemic clamp test

  4. 24 hours glycemic profile

    Time frame: 12 weeks

    24 hours glycemic profile will be measured by the use of continuous glucose monitoring device

  5. Intrahepatic lipid content and composition

    Time frame: 12 weeks

    Intrahepatic lipid content and composition will be measured by magnetic resonance spectroscopy of protons (1H-MRS)

  6. De novo lipogenesis (DNL)

    Time frame: 12 weeks

    DNL will be measured by the use of deuterated water (D2O)

  7. Skeletal muscle glycogen content

    Time frame: 12 weeks

    Muscle glycogen content will be quantified in muscle biopsies

  8. Proteins that regulate oxidative metabolism

    Time frame: 12 weeks

    Content of proteins that regulate oxidative phosphorylation system (OXPHOS) will be quantified in muscle biopsies

  9. Maximal aerobic capacity

    Time frame: 12 weeks

    Maximal aerobic capacity will be measure upon a progressive cycling test

  10. Body weight

    Time frame: 12 weeks

    Body weight will be measured in kilograms

  11. Total muscle mass

    Time frame: 12 weeks

    total muscle mass will be measured in kilograms and/or percentage

  12. Total fat mass

    Time frame: 12 weeks

    Total fat mass will be measured in kilograms and/or percentage

  13. Fat-free mass

    Time frame: 12 weeks

    Fat-free mass will be measured in kilograms and/or percentage

  14. Skeletal muscle mutiomics

    Time frame: 12 weeks

    multiomics will be applied in muscle biopsies

Study contacts

Contact information is provided by the study sponsor or research team.

Rodrigo Mancilla, PhD

CONTACT

[email protected]

+56953676588

Sponsors and collaborators

Lead sponsor

Finis Terrae University

Other

Registry information

Official study title

Effects of High Intensity Interval Training on Skeletal Muscle Insulin Sensitivity in Type 2 Diabetes Patients

Acronym: T2D-HIIT

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Nov 14, 2024
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.